Literature DB >> 7501875

A trichloroethylene risk assessment using a Monte Carlo analysis of parameter uncertainty in conjunction with physiologically-based pharmacokinetic modeling.

W J Cronin1, E J Oswald, M L Shelley, J W Fisher, C D Flemming.   

Abstract

A Monte Carlo simulation is incorporated into a risk assessment for trichloroethylene (TCE) using physiologically-based pharmacokinetic (PBPK) modeling coupled with the linearized multistage model to derive human carcinogenic risk extrapolations. The Monte Carlo technique incorporates physiological parameter variability to produce a statistically derived range of risk estimates which quantifies specific uncertainties associated with PBPK risk assessment approaches. Both inhalation and ingestion exposure routes are addressed. Simulated exposure scenarios were consistent with those used by the Environmental Protection Agency (EPA) in their TCE risk assessment. Mean values of physiological parameters were gathered from the literature for both mice (carcinogenic bioassay subjects) and for humans. Realistic physiological value distributions were assumed using existing data on variability. Mouse cancer bioassay data were correlated to total TCE metabolized and area-under-the-curve (blood concentration) trichloroacetic acid (TCA) as determined by a mouse PBPK model. These internal dose metrics were used in a linearized multistage model analysis to determine dose metric values corresponding to 10(-6) lifetime excess cancer risk. Using a human PBPK model, these metabolized doses were then extrapolated to equivalent human exposures (inhalation and ingestion). The Monte Carlo iterations with varying mouse and human physiological parameters produced a range of human exposure concentrations producing a 10(-6) risk.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7501875     DOI: 10.1111/j.1539-6924.1995.tb00752.x

Source DB:  PubMed          Journal:  Risk Anal        ISSN: 0272-4332            Impact factor:   4.000


  4 in total

Review 1.  Whole body pharmacokinetic models.

Authors:  Ivan Nestorov
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

2.  Assessing Toxicokinetic Uncertainty and Variability in Risk Prioritization.

Authors:  John F Wambaugh; Barbara A Wetmore; Caroline L Ring; Chantel I Nicolas; Robert G Pearce; Gregory S Honda; Roger Dinallo; Derek Angus; Jon Gilbert; Teresa Sierra; Akshay Badrinarayanan; Bradley Snodgrass; Adam Brockman; Chris Strock; R Woodrow Setzer; Russell S Thomas
Journal:  Toxicol Sci       Date:  2019-12-01       Impact factor: 4.849

Review 3.  Topics in cancer risk assessment.

Authors:  S S Olin; D A Neumann; J A Foran; G J Scarano
Journal:  Environ Health Perspect       Date:  1997-02       Impact factor: 9.031

Review 4.  Physiologically based pharmacokinetic models for trichloroethylene and its oxidative metabolites.

Authors:  J W Fisher
Journal:  Environ Health Perspect       Date:  2000-05       Impact factor: 9.031

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.